Cousin et al. evaluated the potential role of CT-based radiomics in predicting treatment response and survival in advanced NSCLC patients treated with PD-1/PD-L1 inhibitors, identifying patients who might not have greater benefit [23]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.